Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 31

1.

A Reactive Antibody Platform for One-Step Production of Antibody-Drug Conjugates through a Diels-Alder Reaction with Maleimide.

St Amant AH, Huang F, Lin J, Lemen D, Chakiath C, Mao S, Fazenbaker C, Zhong H, Harper J, Xu W, Patel N, Adams L, Vijayakrishnan B, Howard PW, Marelli M, Wu H, Gao C, Read de Alaniz J, Christie RJ.

Bioconjug Chem. 2019 Aug 19. doi: 10.1021/acs.bioconjchem.9b00436. [Epub ahead of print]

PMID:
31380623
2.

Design and characterization of homogenous antibody-drug conjugates with a drug-to-antibody ratio of one prepared using an engineered antibody and a dual-maleimide pyrrolobenzodiazepine dimer.

White JB, Fleming R, Masterson L, Ruddle BT, Zhong H, Fazenbaker C, Strout P, Rosenthal K, Reed M, Muniz-Medina V, Howard P, Dixit R, Wu H, Hinrichs MJ, Gao C, Dimasi N.

MAbs. 2019 Apr;11(3):500-515. doi: 10.1080/19420862.2019.1578611. Epub 2019 Mar 5.

PMID:
30835621
3.

Improved Therapeutic Window in BRCA-mutant Tumors with Antibody-linked Pyrrolobenzodiazepine Dimers with and without PARP Inhibition.

Zhong H, Chen C, Tammali R, Breen S, Zhang J, Fazenbaker C, Kennedy M, Conway J, Higgs BW, Holoweckyj N, Raja R, Harper J, Pierce AJ, Herbst R, Tice DA.

Mol Cancer Ther. 2019 Jan;18(1):89-99. doi: 10.1158/1535-7163.MCT-18-0314. Epub 2018 Oct 23.

PMID:
30352801
4.

Preclinical assessment of an antibody-PBD conjugate that targets BCMA on multiple myeloma and myeloma progenitor cells.

Kinneer K, Flynn M, Thomas SB, Meekin J, Varkey R, Xiao X, Zhong H, Breen S, Hynes PG, Fleming R, Bezabeh B, Chen CT, Wetzel L, Chen R, Dimasi N, Tai YT, Anderson KC, Herbst R, Howard PW, Hurt EM, Tice DA.

Leukemia. 2019 Mar;33(3):766-771. doi: 10.1038/s41375-018-0278-7. Epub 2018 Oct 12. No abstract available.

PMID:
30315237
5.

Tuning the Diels-Alder Reaction for Bioconjugation to Maleimide Drug-Linkers.

St Amant AH, Lemen D, Florinas S, Mao S, Fazenbaker C, Zhong H, Wu H, Gao C, Christie RJ, Read de Alaniz J.

Bioconjug Chem. 2018 Jul 18;29(7):2406-2414. doi: 10.1021/acs.bioconjchem.8b00320. Epub 2018 Jun 22.

6.

Preclinical evaluation of a GFRA1 targeted antibody-drug conjugate in breast cancer.

Bosco EE, Christie RJ, Carrasco R, Sabol D, Zha J, DaCosta K, Brown L, Kennedy M, Meekin J, Phipps S, Ayriss J, Du Q, Bezabeh B, Chowdhury P, Breen S, Chen C, Reed M, Hinrichs M, Zhong H, Xiao Z, Dixit R, Herbst R, Tice DA.

Oncotarget. 2018 May 1;9(33):22960-22975. doi: 10.18632/oncotarget.25160. eCollection 2018 May 1.

7.

Design and Synthesis of Cobalt-Based Electrocatalysts for Oxygen Reduction Reaction.

Zhong H, Gong X, Zhang S, Tang P, Li D, Feng Y.

Chem Rec. 2018 Jul;18(7-8):840-848. doi: 10.1002/tcr.201700081. Epub 2017 Dec 29. Review.

PMID:
29286199
8.

Pre-clinical pharmacology of AZD3965, a selective inhibitor of MCT1: DLBCL, NHL and Burkitt's lymphoma anti-tumor activity.

Curtis NJ, Mooney L, Hopcroft L, Michopoulos F, Whalley N, Zhong H, Murray C, Logie A, Revill M, Byth KF, Benjamin AD, Firth MA, Green S, Smith PD, Critchlow SE.

Oncotarget. 2017 May 25;8(41):69219-69236. doi: 10.18632/oncotarget.18215. eCollection 2017 Sep 19.

9.

Fractionated Dosing Improves Preclinical Therapeutic Index of Pyrrolobenzodiazepine-Containing Antibody Drug Conjugates.

Hinrichs MJM, Ryan PM, Zheng B, Afif-Rider S, Yu XQ, Gunsior M, Zhong H, Harper J, Bezabeh B, Vashisht K, Rebelatto M, Reed M, Ryan PC, Breen S, Patel N, Chen C, Masterson L, Tiberghien A, Howard PW, Dimasi N, Dixit R.

Clin Cancer Res. 2017 Oct 1;23(19):5858-5868. doi: 10.1158/1078-0432.CCR-17-0219. Epub 2017 Jun 19.

10.

Preclinical Evaluation of MEDI0641, a Pyrrolobenzodiazepine-Conjugated Antibody-Drug Conjugate Targeting 5T4.

Harper J, Lloyd C, Dimasi N, Toader D, Marwood R, Lewis L, Bannister D, Jovanovic J, Fleming R, D'Hooge F, Mao S, Marrero AM, Korade M 3rd, Strout P, Xu L, Chen C, Wetzel L, Breen S, van Vlerken-Ysla L, Jalla S, Rebelatto M, Zhong H, Hurt EM, Hinrichs MJ, Huang K, Howard PW, Tice DA, Hollingsworth RE, Herbst R, Kamal A.

Mol Cancer Ther. 2017 Aug;16(8):1576-1587. doi: 10.1158/1535-7163.MCT-16-0825. Epub 2017 May 18.

11.

Efficient Preparation of Site-Specific Antibody-Drug Conjugates Using Cysteine Insertion.

Dimasi N, Fleming R, Zhong H, Bezabeh B, Kinneer K, Christie RJ, Fazenbaker C, Wu H, Gao C.

Mol Pharm. 2017 May 1;14(5):1501-1516. doi: 10.1021/acs.molpharmaceut.6b00995. Epub 2017 Mar 16.

PMID:
28245132
12.

Electrocatalytic Cobalt Nanoparticles Interacting with Nitrogen-Doped Carbon Nanotube in Situ Generated from a Metal-Organic Framework for the Oxygen Reduction Reaction.

Zhong H, Luo Y, He S, Tang P, Li D, Alonso-Vante N, Feng Y.

ACS Appl Mater Interfaces. 2017 Jan 25;9(3):2541-2549. doi: 10.1021/acsami.6b14942. Epub 2017 Jan 11.

PMID:
28032991
13.

Insertion of scFv into the hinge domain of full-length IgG1 monoclonal antibody results in tetravalent bispecific molecule with robust properties.

Bezabeh B, Fleming R, Fazenbaker C, Zhong H, Coffman K, Yu XQ, Leow CC, Gibson N, Wilson S, Stover CK, Wu H, Gao C, Dimasi N.

MAbs. 2017 Feb/Mar;9(2):240-256. doi: 10.1080/19420862.2016.1270492.

14.

Straightforward Glycoengineering Approach to Site-Specific Antibody-Pyrrolobenzodiazepine Conjugates.

Thompson P, Ezeadi E, Hutchinson I, Fleming R, Bezabeh B, Lin J, Mao S, Chen C, Masterson L, Zhong H, Toader D, Howard P, Wu H, Gao C, Dimasi N.

ACS Med Chem Lett. 2016 Sep 20;7(11):1005-1008. eCollection 2016 Nov 10.

15.

Rational design, biophysical and biological characterization of site-specific antibody-tubulysin conjugates with improved stability, efficacy and pharmacokinetics.

Thompson P, Fleming R, Bezabeh B, Huang F, Mao S, Chen C, Harper J, Zhong H, Gao X, Yu XQ, Hinrichs MJ, Reed M, Kamal A, Strout P, Cho S, Woods R, Hollingsworth RE, Dixit R, Wu H, Gao C, Dimasi N.

J Control Release. 2016 Aug 28;236:100-16. doi: 10.1016/j.jconrel.2016.06.025. Epub 2016 Jun 18.

PMID:
27327768
16.

IL-6 Inhibition With MEDI5117 Decreases The Fraction of Head and Neck Cancer Stem Cells and Prevents Tumor Recurrence.

Finkel KA, Warner KA, Kerk S, Bradford CR, McLean SA, Prince ME, Zhong H, Hurt EM, Hollingsworth RE, Wicha MS, Tice DA, Nör JE.

Neoplasia. 2016 May;18(5):273-281. doi: 10.1016/j.neo.2016.03.004. Epub 2016 Apr 15.

17.

Genomic Landscape Survey Identifies SRSF1 as a Key Oncodriver in Small Cell Lung Cancer.

Jiang L, Huang J, Higgs BW, Hu Z, Xiao Z, Yao X, Conley S, Zhong H, Liu Z, Brohawn P, Shen D, Wu S, Ge X, Jiang Y, Zhao Y, Lou Y, Morehouse C, Zhu W, Sebastian Y, Czapiga M, Oganesyan V, Fu H, Niu Y, Zhang W, Streicher K, Tice D, Zhao H, Zhu M, Xu L, Herbst R, Su X, Gu Y, Li S, Huang L, Gu J, Han B, Jallal B, Shen H, Yao Y.

PLoS Genet. 2016 Apr 19;12(4):e1005895. doi: 10.1371/journal.pgen.1005895. eCollection 2016 Apr.

18.

A Novel IL6 Antibody Sensitizes Multiple Tumor Types to Chemotherapy Including Trastuzumab-Resistant Tumors.

Zhong H, Davis A, Ouzounova M, Carrasco RA, Chen C, Breen S, Chang YS, Huang J, Liu Z, Yao Y, Hurt E, Moisan J, Fung M, Tice DA, Clouthier SG, Xiao Z, Wicha MS, Korkaya H, Hollingsworth RE.

Cancer Res. 2016 Jan 15;76(2):480-90. doi: 10.1158/0008-5472.CAN-15-0883. Epub 2016 Jan 7.

19.

Hydrolytically Stable Site-Specific Conjugation at the N-Terminus of an Engineered Antibody.

Thompson P, Bezabeh B, Fleming R, Pruitt M, Mao S, Strout P, Chen C, Cho S, Zhong H, Wu H, Gao C, Dimasi N.

Bioconjug Chem. 2015 Oct 21;26(10):2085-96. doi: 10.1021/acs.bioconjchem.5b00355. Epub 2015 Sep 21.

PMID:
26340339
20.

Interleukin-6 Stimulates Defective Angiogenesis.

Gopinathan G, Milagre C, Pearce OM, Reynolds LE, Hodivala-Dilke K, Leinster DA, Zhong H, Hollingsworth RE, Thompson R, Whiteford JR, Balkwill F.

Cancer Res. 2015 Aug 1;75(15):3098-107. doi: 10.1158/0008-5472.CAN-15-1227. Epub 2015 Jun 16.

Supplemental Content

Loading ...
Support Center